Managing adults with screen-detected islet autoantibody positivity: a pragmatic framework.

New disease-modifying therapies, such as teplizumab, offer opportunities to delay the clinical onset of type 1 diabetes but require islet autoantibody screening to identify individuals at increased risk of progression to diabetes. As type 1 diabetes…

Preview only. Read the full abstract at the source